Dabrowski Michael, Ashcroft Frances M, Ashfield Rebecca, Lebrun Philippe, Pirotte Bernard, Egebjerg Jan, Bondo Hansen John, Wahl Philip
Research & Development, Novo Nordisk, Malov, Denmark.
Diabetes. 2002 Jun;51(6):1896-906. doi: 10.2337/diabetes.51.6.1896.
ATP-sensitive K(+) (K(ATP)) channels are activated by a diverse group of compounds known as potassium channel openers (PCOs). Here, we report functional studies of the Kir6.2/SUR1 Selective PCO 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide (NNC 55-9216). We recorded cloned K(ATP) channel currents from inside-out patches excised from Xenopus laevis oocytes heterologously expressing Kir6.2/SUR1, Kir6.2/SUR2A, or Kir6.2/SUR2B, corresponding to the beta-cell, cardiac, and smooth muscle types of the K(ATP) channel. NNC 55-9216 reversibly activated Kir6.2/SUR1 currents (EC(50) = 16 micromol/l). This activation was dependent on intracellular MgATP and was abolished by mutation of a single residue in the Walker A motifs of either nucleotide-binding domain of SUR1. The drug had no effect on Kir6.2/SUR2A or Kir6.2/SUR2B currents. We therefore used chimeras of SUR1 and SUR2A to identify regions of SUR1 involved in the response to NNC 55-9216. Activation was completely abolished and significantly reduced by swapping transmembrane domains 8-11. The reverse chimera consisting of SUR2A with transmembrane domains 8-11 and NBD2 consisting SUR1 was activated by NNC 55-9216, indicating that these SUR1 regions are important for drug activation. [(3)H]glibenclamide binding to membranes from HEK293 cells transfected with SUR1 was displaced by NNC 55-9216 (IC(50) = 105 micromol/l), and this effect was impaired when NBD2 of SUR1 was replaced by that of SUR2A. These results suggest NNC 55-9216 is a SUR1-selective PCO that requires structural determinants, which differ from those needed for activation of the K(ATP) channel by pinacidil and cromakalim. The high selectivity of NNC 55-9216 may prove to be useful for studies of the molecular mechanism of PCO action.
ATP敏感性钾离子(K(ATP))通道可被一类称为钾通道开放剂(PCOs)的多种化合物激活。在此,我们报告了对Kir6.2/SUR1选择性PCO 3 -异丙基氨基 - 7 -甲氧基 - 4H - 1,2,4 -苯并噻二嗪1,1 -二氧化物(NNC 55 - 9216)的功能研究。我们从非洲爪蟾卵母细胞中异源表达Kir6.2/SUR1、Kir6.2/SUR2A或Kir6.2/SUR2B后切除的内向外膜片中记录克隆的K(ATP)通道电流,它们分别对应于K(ATP)通道的β细胞、心脏和平滑肌类型。NNC 55 - 9216可逆性激活Kir6.2/SUR1电流(半数有效浓度(EC(50)) = 16微摩尔/升)。这种激活依赖于细胞内MgATP,并且通过SUR1任一核苷酸结合结构域中沃克A基序的单个残基突变而被消除。该药物对Kir6.2/SUR2A或Kir6.2/SUR2B电流无影响。因此,我们使用SUR1和SUR2A的嵌合体来鉴定SUR1中参与对NNC 55 - 9216反应的区域。通过交换跨膜结构域8 - 11,激活完全被消除且显著降低。由带有跨膜结构域8 - 11的SUR2A和由SUR1组成的NBD2组成的反向嵌合体被NNC 55 - 9216激活,表明这些SUR1区域对药物激活很重要。NNC 55 - 9216可置换转染了SUR1的HEK293细胞膜上的[³H]格列本脲结合(半数抑制浓度(IC(50)) = 105微摩尔/升),并且当SUR1的NBD2被SUR2A的NBD2取代时,这种作用受损。这些结果表明NNC 55 - 9216是一种SUR1选择性PCO,其需要的结构决定因素不同于吡那地尔和克罗卡林激活K(ATP)通道所需的因素。NNC 55 - 9216的高选择性可能被证明对研究PCO作用的分子机制有用。